マーソ(株)
2Q Highlights for the 2026 Fiscal Year | Growth Strategy
YoY increases/decreases in revenue and various profit metrics for the cumulative 2Q. Revenue and backlog growth are particularly notable, signaling future growth. Contributions from corporate entities and DX-related areas are expected to continue.
Key Figures
- Backlog revenue: Unknown
- Advertising revenue: Unknown
- DX revenue: Unknown
AI要約
Overview of the results
For the current period, cumulative 2Q revenue and backlog have exceeded the previous period's results, with particularly strong growth in corporate backlog. In terms of cost structure, reductions in personnel costs and parts of selling, general and administrative expenses are progressing, and movements in operating income and net income versus the same period last year are variable. Signs of business expansion are seen centered on the DX in ADX areas.
Outlook and key initiatives
From the new fiscal year onwards, revenue growth is expected driven by continued expansion of corporate backlog. By optimizing the allocation of advertising, promotions, and development costs, MRSO aims to expand in the health management DX domain. It is anticipated that measures to improve profitability for the full year will continue.
MRSO Inc.
Company overview · Stock price · Financial data · All IR
